Nuo Therapeutics, Inc. revenue by segment AURX

Annual Quarterly

Nuo Therapeutics, Inc. splits its revenue into 4 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Aurix And Private Label Kits at $2.8 million, 84% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Jun 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2015 Dec 31, 2015	FY 2014 Dec 31, 2014	FY 2013 Dec 31, 2013
Revenue	5	3	1	1	0	0	1	1	12	8	12
Aurix And Private Label Kits	—	3 share 83.8%	—	—	—	—	—	—	—	—	—
Product	—	—	1 +124.3% share 100.0%	1 +442.1% share 100.0%	0 share 100.0%	—	—	—	—	—	—
Aurix And Private Label Centrifuge Devices	—	0 share 9.4%	—	—	—	—	—	—	—	—	—
License	—	0 share 6.8%	—	—	—	—	—	—	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as: AURX (OTC)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Houston, TX
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1091596
Former names: Nuo Therapeutics, Inc (until Dec 23, 2014); CYTOMEDIX INC (until Oct 8, 2014); AUTOLOGOUS WOUND THERAPY INC (until Apr 10, 2000); AUTOLOGOUS WOUND TRERAPY INC (until Mar 23, 2000)

Other Surgical & Medical Instruments & Apparatus companies

All 151 Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.